PMID- 28277353
OWN - NLM
STAT- MEDLINE
DCOM- 20170621
LR  - 20180610
IS  - 1873-233X (Electronic)
IS  - 0029-7844 (Linking)
VI  - 129
IP  - 4
DP  - 2017 Apr
TI  - Risk of Adverse Pregnancy Outcome After Paternal Exposure to Methotrexate Within 
      90 Days Before Pregnancy.
PG  - 707-714
LID - 10.1097/AOG.0000000000001936 [doi]
AB  - OBJECTIVE: To study the association between paternal exposure to methotrexate
      within the 90-day period before pregnancy and congenital malformations and
      stillbirth in the offspring. METHODS: We conducted a nationwide register study.
      Our cohort consisted of all live births in Denmark between 1997 and 2011
      identified from the Medical Birth Registry. Methotrexate-exposed fathers were
      identified from the National Prescription Registry. From the national Hospital
      Registry we identified paternity, live births, and stillbirths as well as
      discharge diagnoses on congenital malformations. RESULTS: We identified 849,676
      live births with known paternity. There were 127 live births of
      methotrexate-exposed fathers. Of these, four (3.2%) had major malformations
      compared with 28,814 (3.4%) of the unexposed. The odds ratio (OR) for major
      congenital malformation among exposed fathers compared with unexposed was 0.93
      (95% confidence interval [CI] 0.34-2.51) and when adjusted for year of birth,
      maternal age, educational length, household income, and parity, the adjusted OR
      was 1.01 (95% CI 0.37-2.74). There were no stillbirths in the
      methotrexate-exposed group compared with 2,541 (0.3%) in the unexposed group and 
      no increased risk of preterm birth (adjusted OR 1.31, 95% CI 0.66-2.59) among the
      children from exposed fathers. CONCLUSION: We found no association between
      paternal exposure to methotrexate within 90 days before pregnancy and congenital 
      malformations, stillbirths, or preterm birth. Available data suggest that
      prepregnancy paternal methotrexate exposure should not be of major concern.
      Multinational recommendations should be changed accordingly.
FAU - Eck, Lasse Karlsen
AU  - Eck LK
AD  - Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg,
      and the Faculty of Health and Medical Sciences, University of Copenhagen,
      Copenhagen, the Department of Rheumatology, Copenhagen University Hospital
      Rigshospitalet, Glostrup, and the Department of Urology, Copenhagen University
      Hospital Roskilde, Roskilde, Denmark; the Department of Obstetrics and
      Gynecology, University of Illinois at Chicago, Chicago, Illinois.
FAU - Jensen, Thomas Bo
AU  - Jensen TB
FAU - Mastrogiannis, Dimitrios
AU  - Mastrogiannis D
FAU - Torp-Pedersen, Arendse
AU  - Torp-Pedersen A
FAU - Askaa, Bjarke
AU  - Askaa B
FAU - Nielsen, Torben Kjaer
AU  - Nielsen TK
FAU - Poulsen, Henrik Enghusen
AU  - Poulsen HE
FAU - Jimenez-Solem, Espen
AU  - Jimenez-Solem E
FAU - Andersen, Jon Traerup
AU  - Andersen JT
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Obstet Gynecol
JT  - Obstetrics and gynecology
JID - 0401101
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Prescription Drugs)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Cohort Studies
MH  - Congenital Abnormalities/*epidemiology
MH  - Denmark/epidemiology
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents/administration & dosage/adverse effects
MH  - Infant, Newborn
MH  - Male
MH  - *Methotrexate/administration & dosage/adverse effects
MH  - *Paternal Exposure/adverse effects/statistics & numerical data
MH  - Pregnancy
MH  - Premature Birth/*epidemiology
MH  - Prescription Drugs/administration & dosage/adverse effects
MH  - Registries/statistics & numerical data
MH  - Risk Assessment
MH  - Statistics as Topic
MH  - Stillbirth/*epidemiology
EDAT- 2017/03/10 06:00
MHDA- 2017/06/22 06:00
CRDT- 2017/03/10 06:00
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2017/06/22 06:00 [medline]
PHST- 2017/03/10 06:00 [entrez]
AID - 10.1097/AOG.0000000000001936 [doi]
PST - ppublish
SO  - Obstet Gynecol. 2017 Apr;129(4):707-714. doi: 10.1097/AOG.0000000000001936.